Amyris Aprinnova Joint Venture Launches Pharmaceutical Grade Neossance Squalane USP – Opens New Market Among FDA Regulated ...
February 08 2018 - 8:30AM
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company,
today announced that Aprinnova, its joint venture with NIKKOL GROUP
(“NIKKOL”), has launched pharmaceutical grade Neossance® Squalane
USP. This new material meets the industry standards required by the
United States Pharmacopeia (USP) and the National Formulary (NF)
for drug actives and pharmaceutical excipients, which are used by
regulatory agencies and manufacturers to ensure products have the
appropriate identity, quality, purity, and consistency. As a
result, Aprinnova is now able to supply these industries with
FDA-regulated sugarcane-derived squalane, which was previously
unavailable to these markets since shark-derived squalane was the
only source reference in the regulatory monograph for squalane.
Amyris’s Aprinnova cosmetic ingredients joint
venture has now delivered over 50% annual revenue growth since the
joint venture was announced and is the leading source of one of the
world’s leading natural skin nourishment ingredients. This approval
enables significant expansion of this business across numerous
product applications. These include topical and dermal cosmetic
applications such as therapeutic skin creams and ointments.
“We are very pleased to have met the USP and NF
requirements, which showcases our adherence to a philosophy of
manufacturing and distributing the highest performance, sustainable
products through a best-in-class production process,” said Caroline
Hadfield, Senior Vice President of Personal Care at Amyris. “We are
delighted to provide a sustainable and naturally-sourced squalane
to this important new market for Aprinnova while providing our
customers and their end market customers with non-animal,
cruelty-free high-performance ingredients for a growing variety of
products.”
About Amyris
Amyris is the integrated renewable products company that is
enabling the world’s leading brands to achieve sustainable growth.
Amyris applies its innovative bioscience solutions to convert plant
sugars into hydrocarbon molecules and produce specialty ingredients
and consumer products. The company is delivering its No Compromise®
products across a number of markets, including specialty and
performance chemicals, flavors and fragrances, cosmetics
ingredients, pharmaceuticals, and nutraceuticals. More information
about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any
statements other than statements of historical fact could be deemed
to be forward-looking statements. These forward-looking statements
include, among other things, statements regarding future events
(such as the expected expansion of the Aprinnova business across
numerous product applications, including topical and dermal
cosmetic applications such as therapeutic skin creams and
ointments), that involve risks and uncertainties. These statements
are based on management's current expectations and actual results
and future events may differ materially due to risks and
uncertainties, including risks related to Amyris's liquidity and
ability to fund operating and capital expenses, potential delays or
failures in development, production and commercialization of
products, risks related to Amyris's reliance on third parties, and
other risks detailed from time to time in filings Amyris makes with
the Securities and Exchange Commission, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Amyris disclaims any obligation to update information
contained in these forward-looking statements whether as a result
of new information, future events, or otherwise.
Amyris, the Amyris logo, Aprinnova, the Aprinnova logo, No
Compromise, and Neossance are trademarks or registered trademarks
of Amyris, Inc. in the U.S. and/or other countries. All other
trademarks are the property of their respective owners.
Contact:Peter DeNardoDirector, Investor
Relations and Corporate CommunicationsAmyris, Inc. +1 (510)
740-7481investor@amyris.compr@amyris.com
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Apr 2024 to May 2024
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From May 2023 to May 2024